digoxin vs placebo | No demonstrated result suggested exacerbation of heart failure by 62% (not demonstrated) suggested hospitalisation for heart failure by 23% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
hospitalisation for cardiovascular causes | 0.92 [0.83 1.01] | p=1.00 | 0 | 6800 | 1 | Digitalis Investigation Group (DIG), | exacerbation of heart failure | 0.38 [0.25 0.56] | p=0.04 | 0 | 1234 | 12 | Fleg,Lee,Taggart,Captopril-Digoxin Multicenter Research Group (CDMRG),German and Austrian Xamoterol Study,Guyatt,DiBianco,Pugh,Blackwood,Radiance,Proved,DIMT, | Cardiovascular death | 0.99 [0.90 1.09] | p=1.00 | 0 | 6800 | 1 | Digitalis Investigation Group (DIG), | hospitalisation for heart failure | 0.77 [0.69 0.85] | p=0.04 | 0 | 6978 | 2 | Radiance,Digitalis Investigation Group (DIG), | All cause death | 0.99 [0.90 1.09] | p=1.00 | 0 | 7755 | 8 | Captopril-Digoxin Multicenter Research Group (CDMRG),German and Austrian Xamoterol Study,DiBianco,Blackwood,Radiance,Proved,DIMT,Digitalis Investigation Group (DIG), | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |